Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

20P - Molecular mechanism of MK2-CRABP2 signaling pathway mediating the progression of lung adenocarcinoma


16 Sep 2021


ePoster Display


Basic Science

Tumour Site

Non-Small Cell Lung Cancer


Jianxiong Deng


Annals of Oncology (2021) 32 (suppl_5): S361-S375. 10.1016/annonc/annonc684


J. Deng, F. Zhong

Author affiliations

  • Oncology Dept., The First Affiliated Hospital of Nanchang University, 330006 - Nanchang/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 20P


The morbidity and mortality of lung cancer rank the first among malignant tumors in China. EGFR-TKIs has achieved good efficacy in advanced lung adenocarcinoma with EGFR-positive, however, drug resistance and rapid progress of some patients are still inevitable. Therefore, it is of great significance to find new therapeutic targets. Abnormally activated transcriptional regulators are involved in many biological processes of the development of malignant tumors, further exploration of their functional mechanisms is expected to provide a new direction for targeted tumor therapy.


TRRUST and CHIPBase databases of transcriptional regulatory factor and TCGA databases were integrated to screen the transcriptional regulatory factors with significantly different expression in lung adenocarcinoma. The prediction of interacting molecules was performed on the Linkedomics, and preliminary verification was performed using WB. The clinicopathological data of lung adenocarcinoma patients with survival data from GEO and TCGA databases were downloaded to analyze the effect of CRABP2 and MK2 expression on survival prognosis.


Transcription and protein expression of CRABP2 were significantly up-regulated in lung adenocarcinoma. Bioinformatics analysis showed that MK2 interacted with CRABP2, and CRABP2protein decreased significantly after knockdown of Mk2 protein expression. The overall survival of lung adenocarcinoma patients with high CRABP2 and MK2 expressions were worse than that of the low expression group (P = 3.4e-04 and 6.5e-05, respectively).


MK2 may phosphorylate CRABP2 to mediate the progression of lung adenocarcinoma, and the MK2-CRABP2 signaling pathway is expected to become a biomarker or a new target for drug therapy of lung adenocarcinoma. However, further molecular experiments are needed for further exploration and verification.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.